This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
It is the third rail of Twitter, Maintenance of Certification. But ASN wanted to tackle this head on with a public position and Twitter chat. Take a look at the analytics, storify and transcript.
NephJC has never seen a chat with as many participants or as many tweets,
First tweet was last monday and look at the response! Thanks for getting the word out there!
